Bavarian Nordic Research Institute GmbH
This article was originally published in Start Up
Executive Summary
Gene Therapy. Bavarian Nordic avoids concerns about the pathogenicity of viral vectors with treatments based on modified vaccinia ankara (MVA) vectors and retroviral promoter conversion vectors. The company's MVA programs are focused on cancer, HIV infection and Dengue fever. It is developing {ProCon} for treatment of cancers of the breast and pancreas and potentially restenosis.